Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Busting Up Bacterial Gangs

New antibiotics that disrupt microbial communication could help cystic fibrosis patients.

By speaking the language of bacteria, researchers from the State University of New York at Buffalo have made a critical advance in the development of what could be a new class of antibiotics. Such drugs could eventually combat a host of currently incurable infections-including those caused by Pseudomonas aeruginosa, a bacterium that chronically infects nearly 70 percent of cystic-fibrosis patients.

Most antibiotics block bacteria’s ability to synthesize proteins or cell membranes, says biochemist Hiroaki Suga, who led the effort, but “our approach targets a completely different system.” That system is a means of communication that many species of bacteria use to gang up on their hosts. Alone, these bacteria are often harmless and susceptible to regular antibiotics. But once they reach a critical density and begin to communicate through chemicals they emit, they cooperate to boost their virulence and evade traditional treatments by, for example, forming slimy biofilms.

Previous efforts to develop drugs that disrupt bacterial communication have focused on naturally occurring chemicals. Suga instead synthesized a library of molecules from scratch by tinkering with the structure of one of the communication chemicals found in Pseudomonas. Several of Suga’s new molecules blocked the bacteria’s conversation; such molecules could be used with conventional antibiotics to more effectively target the microbes.

This story is part of our July/August 2003 Issue
See the rest of the issue
Subscribe

Suga’s molecules aren’t strong enough to be used as drugs, says the University of Texas at Austin’s Walter Fast, a medicinal chemist, but their development marks an important step forward. And, Fast says, “Hiro’s approach is definitely generalizable to other bacteria.” Suga has filed a patent on the technology and is fielding corporate interest. “We hope to discover more potent antagonists,” he says, “so that we can get closer to developing a real drug in the future.” Such drugs could bust up even the toughest bacterial gangs.

Photo courtesy of Chemistry & Biology, vol 10, no 1, 2003, pp81-89, Smith et al: “Induction and Inhibition of Pseudomonas aeruginosa…”1 figure.

Cut off? Read unlimited articles today.

Become an Insider
Already an Insider? Log in.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Online Only.
  • Insider Online Only {! insider.prices.online !}*

    {! insider.display.menuOptionsLabel !}

    Unlimited online access including articles and video, plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.